Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 4/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | PLA2G6 | O60733 | 2/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.36 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.35 |
| ▸ | TACR2 | P21452 | 1/20 | 0.35 |
| ▸ | CCKBR | P32239 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12869515 | 1.00 | NAAA (0.41) | NAAABCHEACHEPSEN1PSEN2 | |
| SCHEMBL12869511 | 1.00 | NAAA (0.41) | NAAABCHEACHEPSEN1PSEN2 | |
| SCHEMBL10120664 | 0.90 | NAAA (0.43) | NAAABCHEACHEPSEN1PSEN2 | |
| SCHEMBL18371660 | 0.90 | NAAA (0.43) | NAAABCHEACHEPSEN1PSEN2 | |
| SCHEMBL25495993 | 0.90 | NAAA (0.43) | NAAABCHEACHEPSEN1PSEN2 | |
| SCHEMBL16805385 | 0.90 | NAAA (0.43) | NAAABCHEACHEPSEN1PSEN2 | |
| SCHEMBL18080620 | 0.90 | NAAA (0.43) | NAAABCHEACHEPSEN1PSEN2 | |
| SCHEMBL10177147 | 0.89 | NAAA (0.41) | NAAABCHEACHEPSEN1PSEN2 | |
| SCHEMBL18522464 | 0.89 | NAAA (0.41) | NAAABCHEACHEPSEN1PSEN2 | |
| SCHEMBL16727631 | 0.89 | NAAA (0.43) | NAAABCHEACHEPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250121-A1 | METHOD FOR PREPARING GLUCOPYRANOSYL DERIVATIVES AND INTERMEDIATES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-9828366-B2 | Bicyclic derivatives and pharmaceutical composition including the same | HANMI PHARM. CO., LTD. (KR) | 2017-11-28 | — | — | US | disclosed |
| US-20170066750-A1 | BICYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | HANMI PHARM. CO., LTD. (KR) | 2017-03-09 | — | — | US | disclosed |
| US-9573959-B2 | Methods for preparing SGLT2 inhibitors | MSD INTERNATIONAL GMBH (CH) | 2017-02-21 | — | — | US | disclosed |
| US-9434670-B2 | Family of aryl, heteroaryl, O-aryl and O-heteroaryl carbasugars | TFCHEM (FR) | 2016-09-06 | — | — | US | disclosed |
| US-9371303-B2 | Diphenylmethane derivatives as SGLT2 inhibitors | GREEN CROSS CORPORATION (KR) | 2016-06-21 | — | — | US | disclosed |
| US-9340521-B2 | Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives | GREEN CROSS CORPORATION (KR) | 2016-05-17 | — | — | US | disclosed |
| US-20160046646-A1 | METHODS FOR PREPARING SGLT2 INHIBITORS | PFIZER INC. | 2016-02-18 | — | — | US | disclosed |
| US-20150152075-A1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | GREEN CROSS CORPORATION (KR) | 2015-06-04 | — | — | US | disclosed |
| US-9034921-B2 | Diphenylmethane derivatives as SGLT2 inhibitors | GREEN CROSS CORPORATION (KR) | 2015-05-19 | — | — | US | disclosed |
| US-8586550-B2 | Thiazole derivatives as SGLT2 inhibitors and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2013-11-19 | — | — | US | disclosed |
| US-8541380-B2 | C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same | GREEN CROSS CORPORATION (KR) | 2013-09-24 | — | — | US | disclosed |
| US-20130211064-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8486897-B2 | C-aryl glycoside compounds for the treatment of diabetes and obesity | TFCHEM (FR) | 2013-07-16 | — | — | US | disclosed |
| US-8440803-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20130090298-A1 | Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same | GREEN CROSS CORPORATION (KR) | 2013-04-11 | — | — | US | disclosed |
| US-20120101051-A1 | NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2012-04-26 | — | — | US | disclosed |
| US-20120071645-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120021515-A1 | OLIGOMERIC COMPOUNDS AND METHODS | ISIS PHARMACEUTICALS, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20110034402-A1 | C-ARYL GLYCOSIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND OBESITY | TFCHEM | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090298-A1 | Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same | SLC5A2, SLC5A1, SLC10A2 | NAAA 3504/4885BCHE 4547/4885ACHE 4412/4885 |
| US-20160046646-A1 | METHODS FOR PREPARING SGLT2 INHIBITORS | SLC5A2, SLC5A1, SLC2A8 | NAAA 577/4885BCHE 3448/4885ACHE 4808/4885 |
| US-20120101051-A1 | NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | SLC5A2, SLC5A1, SLC2A2 | NAAA 2233/4885BCHE 3932/4885ACHE 4657/4885 |
| US-20120021515-A1 | OLIGOMERIC COMPOUNDS AND METHODS | HNRNPH1, RNASEH1, SNRPE | NAAA 2623/4885BCHE 3693/4885ACHE 3823/4885 |
| US-20110034402-A1 | C-ARYL GLYCOSIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND OBESITY | SLC5A2, SLC5A1, GPR119 | NAAA 2298/4885BCHE 919/4885ACHE 2584/4885 |
| US-20230250121-A1 | METHOD FOR PREPARING GLUCOPYRANOSYL DERIVATIVES AND INTERMEDIATES THEREOF | SLC5A2, SLC5A1, UGGT1 | NAAA 1377/4885BCHE 3595/4885ACHE 4246/4885 |
| US-20150152075-A1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | SLC5A2, SLC5A1, SLC2A8 | NAAA 2380/4885BCHE 4542/4885ACHE 4633/4885 |
| US-20120071645-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | HNRNPM, POLM, RNMT | NAAA 2991/4885BCHE 4560/4885ACHE 4388/4885 |
| US-20170066750-A1 | BICYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | SLC5A1, SLC5A2, GPR119 | NAAA 2565/4885BCHE 3228/4885ACHE 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.